Home / Market News / $BIIB
benzinga Corporate Catalyst Impact 55/100 ● negative

RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256

Oct 8, 2026, 2:00 PM UTC · Primary ticker $BIIB

RBC Capital analyst Brian Abrahams reiterated an Outperform rating on Biogen but slightly reduced the price target from $260 to $256. This indicates a continued positive outlook on the company's fundamentals, despite a minor adjustment to its valuation.

RBC Capital's analyst Brian Abrahams maintained an 'Outperform' rating for Biogen, signaling continued confidence in the company's long-term prospects. However, the price target was slightly lowered from $260 to $256. This minor adjustment suggests a recalibration of valuation, possibly due to updated financial models, market conditions, or competitive landscape, rather than a fundamental shift in the company's outlook. For traders, this is a relatively neutral event in the short term, as the core positive rating remains. The slight price target reduction might cause a minor dip or sideways movement, but the overarching 'Outperform' suggests a long-term opportunity for investors who believe in the analyst's thesis.

$BIIB neutral Analyst rating maintained, price target slightly lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.